In Vitro and In Silico Analyses of New Cinnamid and Rosmarinic Acid-Derived Compounds Biosynthesized in Escherichia coli as Leishmania amazonensis Arginase Inhibitors

Author(s)

Come, Julio Abel Alfredo dos Santos Simone ; Zhuang, Yibin ; Li, Tianzhen ; Brogi, Simone ; Gemma, Sandra ; Liu, Tao ; da Silva, Edson Roberto

• Document type: Journal article
• Source: PATHOGENS; v. 11, n. 9, p. 14-pg., 2022-09-01.

Abstract

Arginase is a metalloenzyme that plays a central role in Leishmania infections. Previously, rosmarinic and caffeic acids were described as antileishmanial agents and as Leishmania amazonensis arginase inhibitors. Here, we describe the inhibition of arginase in L. amazonensis by rosmarinic acid analogs (1-7) and new caffeic acid-derived amides (8-10). Caffeic acid esters and amides were produced by means of an engineered synthesis in E. coli and tested against L. amazonensis arginase. New amides (8-10) were biosynthesized in E. coli cultured with 2 mM of different combinations of feeding substrates. The most potent arginase inhibitors showed Ki(s) ranging from 2 to 5.7 mu M. Compounds 2-4 and 7 inhibited L. amazonensis arginase (L-ARG) through a noncompetitive mechanism whilst compound 9 showed a competitive inhibition. By applying an in silico protocol, we determined the binding mode of compound 9. The competitive inhibitor of L-ARG targeted the key residues within the binding site of the enzyme, establishing a metal coordination bond with the metal ions and a series of hydrophobic and polar contacts supporting its micromolar inhibition of L-ARG. These results highlight that dihydroxycinnamic-derived compounds can be used as the basis for developing new drugs using a powerful tool based on the biosynthesis of arginase inhibitors. (AU)

• FAPESP's process: 17/06917-4 - Study of the polyamine synthesis pathway and trypanothione synthesis for the development of new drugs for the treatment of leishmaniasis
• Grantee: Edson Roberto da Silva
• Support Opportunities: Regular Research Grants